Antibody levels and protection after hepatitis b vaccine: results of a 22-year follow-up study and response to a booster dose

Journal of Infectious Diseases

Volumn 200, Issue 9, 2009, Pages 1390-1396

  McMahon, Brian J ^a,b   Dentinger, Catherine M ^b,d   Bruden, Dana ^b   Zanis, Carolyn ^b   Peters, Helen ^b   Hurlburt, Debbie ^b   Bulkow, Lisa ^b   Fiore, Anthony E ^c   Bell, Beth P ^c   Hennessy, Thomas W ^b  

^a ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^b NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 72849153267     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/606119     Document Type: Article

References (25)

1. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17: 1730-1733
2. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1-31.
3. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-792
4. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-341
5. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415-1420
6. Van der Sande MAB, Waight P, Mendy M, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-1535 (Pubitemid 43794582) (Pubitemid 43794582)
7. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004; 23:650-655
8. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis-B-infection with vaccine in Yupik Eskimos - demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 1985; 121:914-923
9. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis 1997; 175:674-677 (Pubitemid 27086173)
10. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity an efficacy of hepatitis-B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362-2366
11. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195:5-11.
12. Garwood F. Fiducial limits for the poisson distribution. Biometrika 1936; 46:441-453
13. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley & Sons, 2000.
14. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133:1452-1457 (Pubitemid 350029740) (Pubitemid 350029740)
15. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis 1998; 26:933-937 (Pubitemid 28180332)
16. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis-B vaccine-demonstration of efficacy in a controlled clinical-trial in a high-risk population in the United-States. N Engl J Med 1980; 303:833-841
17. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis-B with vaccine: report of the Centers for Disease Control multicenter efficacy trial among homosexual men. Ann Intern Med 1982; 97:362-366
18. Barash C, Conn MI, DiMarino AJ, Marzano J, Allen ML. Serologic hepatitis B immunity in vaccinated health care workers. Arch Intern Med 1999; 159:1481-1483 (Pubitemid 29302889) (Pubitemid 29302889)
19. Milne A, Hopkirk N, Moyes CD. Hepatitis-B vaccination in children-persistence of immunity at 9 years. J Med Virol 1994; 44:113-114 (Pubitemid 24324001) (Pubitemid 24324001)
20. Pasko MT, Beam TR. Persistence of anti-HBs among health-care personnel immunized with hepatitis-B vaccine. Am J Public Health 1990; 80:590-593
21. Tabor E, Cairns J, Gerety RJ, Bayley AC. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol 1993; 40:204-209 (Pubitemid 23204096)
22. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001; 19:4081-4085
23. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941-945
24. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-1426
25. Samandari T, Fiore AE, Negus S, et al. Differences in response to hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:e373-81.